Methadone Maintenance Patients’ Knowledge, Attitudes, Beliefs, and Experiences Concerning Treatment for Hepatitis C Virus Infection

References

• Amon, J. J., Garfein, R. S., Ahdieh-Grant, L., Armstrong, G., Ouellet, L. J., Latka, M. H., (2008). Prevalence of hepatitis C virus infection among injection drug users in the United States, 1999–2004. Clinical Infectious Diseases, 46:1852–1858.
   PubMed Web of Science ®Google Scholar
• Astone, J. A., Strauss, S. M., Munoz-Plaza, C., Hagan, H., Des Jarlais, D. C. (2005). Providing support to drug users infected with hepatitis C: the role of methadone maintenance treatment staff. Journal of Maintenance in the Addictions, 3(1):33–45.
   Google Scholar
• Backmund, M., Meyer, K., Von Zielonka, M., Eichenlaub, D. (2001). Treatment of hepatitis C infection in injection drug users. Hepatology, 34(1):188–193.
   PubMed Web of Science ®Google Scholar
• Batki, S. L., Cornell, M. E., Peek, R. M. H. (2002, June). Hepatitis C in an upstate New York methadone maintenance treatment program: preliminary analysis. (oral presentation). Annual Meeting of the College on the Problems of Drug Dependence, Quebec City.
   Google Scholar
• Best, D., Noble, A., Finch, E., Gossop, M., Sidwell, C., Stang, J. (1999). Accuracy of perceptions of hepatitis B and C status: cross-sectional investigation of opiate addicts in treatment. BMJ, 319:290–291.
   PubMed Web of Science ®Google Scholar
• Biener, L., Abrams, D. B. (1991). The contemplation ladder: validation of a measure of readiness to consider smoking cessation. Health Psychology, 10(5):360–365.
   PubMed Web of Science ®Google Scholar
• Bonkovsky, H. L., Tice, A. D., Yapp, R. G., Bodenheimer, H. C., Monto, A., Rossi, S. J., (2008). Efficacy and safety of peginterferon alpha-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. American Journal of Gastroenterology, 103:2757–2765.
   PubMed Web of Science ®Google Scholar
• Carey, J., Perlman, D. C., Friedmann, P., Kaplan, W. M., Nugent, A., Deutscher, M., (2005). Knowledge of hepatitis among drug injectors at a syringe exchange program. Journal of Substance Abuse Treatment, 29:47–53.
   PubMed Web of Science ®Google Scholar
• Cawthorne, C. H., Rudat, K. R., Burton, M. S., Brown, K. E., Luxon, B. A., Janney, C. G., (2002). Limited success of HCV antiviral therapy in United States veterans. American Journal of Gastroenterology, 91(1):149–159.
   Google Scholar
• Crofts, N., Jolley, D., Kaldor, J., van Beek, I., Wodak, A. (1997). Epidemiology of hepatitis C virus infection among injecting drug users in Australia. Journal of Epidemiology Community Health, 51(6):692–697.
   PubMed Web of Science ®Google Scholar
• Dalgard, K., Bjoro, K., Hellum, K., Myrvang, B., Skaug, K., Gutigard, B., (2002). Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. European Addiction Research, 8:45–49.
   PubMed Web of Science ®Google Scholar
• Diaz, T., Des Jarlais, D. C., Vlahov, D., Perlis, T. E., Edwards, V., Friedman, S. R., (2001). Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. American Journal of Public Health, 91(1):23–30.
   PubMed Web of Science ®Google Scholar
• Doab, A., Treloar, C., Dore, G. L. (2005). Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Disease, 40(S5):S313–S187.
   PubMed Web of Science ®Google Scholar
• Dore, G. J., Law, M., MacDonald, M., Kaldor, J. M. (2003). Epidemiology of hepatitis C virus infection in Australia. Journal of Clinical Virology, 26:171–184.
   PubMed Web of Science ®Google Scholar
• Edlin, B. R., Seal, K. H., Lorvick, J., Kral, A. H., Ciccarone, D. H., Moore, L. D., (2001). Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?? New England Journal of Medicine, 345(3):211–215.
   PubMed Web of Science ®Google Scholar
• Fabris, P., Tositti, G., Giordani, M. T., Baldo, V., Grasso, A., Pignattari, E., (2006). Assessing patients’ understanding of hepatitis C virus infection and its impact on their lifestyle. Alimentary Pharmacology and Therapeutic, 23(8):1161–1170.
   PubMed Web of Science ®Google Scholar
• Falck-Ytter, Y., Kale, H., Mullen, K. D., Sarbah, S. A., Sorescu, L. (2002). Surprisingly small effect of antiviral treatment in patients with hepatitis C. Annals of Internal Medicine, 136(4):288–292.
   PubMed Web of Science ®Google Scholar
• Ferrando, S. J., Batki, S. L. (2000). Substance abuse and HIV infection. New Directions for Mental Health Service, 87:57–67.
   Google Scholar
• Garfein, R. S., Doherty, M. C., Monterroso, E. R., Thomas, D. L., Nelson, K. E., Vlahov, D. (1998). Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 18(Suppl. 1):S11–S19.
   PubMedGoogle Scholar
• Grebely, J., Genoway, K. A., Raffa, J. D., Dhadwal, G., Rajan, T. Showler, G., (2008). Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug and Alcohol Dependence, 93:141–147.
   PubMed Web of Science ®Google Scholar
• Gupta, K., Romney, D., Briggs, M., Benker, K. (2007). Effects of a brief educational program on knowledge and willingness to accept treatment among patients with hepatitis C at inner-city hospitals. Journal of Community Health, 32(4):221–230.
   PubMed Web of Science ®Google Scholar
• Hagan, H., Des Jarlais, D. C., Stern, R., Lelutiu-Weinberger, C., Scheinmann, R., Stauss, S., (2007). HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. International Journal of Drug Policy, 18:341–351.
   PubMed Web of Science ®Google Scholar
• Hagan, H., Thiede, H., Weiss, N. S., Hopkins, S. G., Duchin, J. S., Alexander, E. R. (2001). Sharing of drug preparation equipment a risk factor for hepatitis C. American Journal of Public Health, 91:42–46.
   PubMed Web of Science ®Google Scholar
• Hahn, J. A., Page-Shafer, K., Lum, P. J., Bourgois, P., Stein, E., Evans, J. L., (2002). Hepatitis C virus seroconversion among young injection drug users: relationships and risks. Journal of Infectious Diseases, 186:1558–1564.
   PubMed Web of Science ®Google Scholar
• Hallinan, R., Byrne, A., Amin, J., Dore, G. J. (2005). Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. Journal of Gastroenterology and Hepatology, 20(7):1082–1086.
   PubMed Web of Science ®Google Scholar
• Heimer, R., Clair, S., Grau, L. E., Bluthenthal, R. N., Marshall, P. A., Singer, M. (2002). Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction, 97:1277–1287.
   PubMed Web of Science ®Google Scholar
• Jowett, S. L., Agarwal, K., Smith, B. C., Craig, W., Hewett, M., Bassendine, D., (2001). Managing chronic hepatitis C acquired through intravenous drug use. QJM, 94:153–158.
   PubMed Web of Science ®Google Scholar
• Krantz, M. J., Mehler, P. S. (2004). Treating opioid dependence: growing implications for primary care. Archives of Internal Medicine, 164(3):77–88.
   PubMedGoogle Scholar
• Kwiatkowski, C. F., Booth, R. E. (2001). Methadone maintenance as HIV risk reduction with street-recruited injection drug users. Journal of Acquired Immune Deficiency Syndromes, 26;483–489.
   PubMed Web of Science ®Google Scholar
• Lavanchy, D. (2009). The global burden of hepatitis. Liver International: Official Journal of the International Association for the Study of the Liver, 29(Suppl. 1):S74–S81.
   PubMed Web of Science ®Google Scholar
• Litwin, A. H., Soloway, I., Gourevitch, M. N. (2005). Integrating services for injection drug users infected with hepatitis C with methadone maintenance treatment: challenges and opportunities. Clinical Infectious Diseases, 40:S339–S345.
   PubMed Web of Science ®Google Scholar
• Mauss, S., Berger, F., Goelz, J., Jacob, B., Schutz, G. (2004). A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology, 40:120–124.
   PubMed Web of Science ®Google Scholar
• McCarthy, J. J., Flynn, N. (2001). Hepatitis C in methadone maintenance patients: prevalence and public policy implications. Journal of Addictive Diseases, 20(1):19–31.
   PubMed Web of Science ®Google Scholar
• Mehta, S. H., Genberg, B. L., Astemborski, J., Kavasery, R., Kirk, G. D., Vlahov, D., (2008). Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health, 33:126–133.
   PubMed Web of Science ®Google Scholar
• Metzger, D. S., Woody, G. E., McLellan, A. T., O’Brien, C.P., Druley, P., Navaline, H., (1993). Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes, 6(9):1049–1056.
   PubMed Web of Science ®Google Scholar
• Morrill, J. A., Shrestha, M., Grant, R. (2005). Barriers to the treatment of hepatitis C: patient, provider, and system factors. Journal of General Internal Medicine, 20:754–758.
   PubMed Web of Science ®Google Scholar
• Moss, A. R., Vranizan, K., Gorter, R., Bacchetti, P., Watters, J., Osmaond, D. (1994). HIV seroconversion in intravenous drug users in San Francisco, 1985–1990. AIDS, 8:223–231.
   PubMed Web of Science ®Google Scholar
• Munoz-Plaza, C. E., Strauss, S., Astone-Tweerell, J., Des Jarlais, D., Gwadz, M., Hagan, H., (2008). Exploring drug users’ attitudes and decisions regarding hepatitis C (HCV) treatment in the U.S. International Journal of Drug Policy, 19:71–78.
   PubMed Web of Science ®Google Scholar
• Murrill, C. S., Weeks, H., Castrucci, B. C., Weinstock, H. S., Bell, B. P., Spruill, C., (2002). Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. American Journal of Public Health, 92(3):385–387.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (NIH). (2002). National Institutes of Health consensus development conference statement: management of hepatitis C, June 10–12. Hepatology, 36(Suppl.):S3–S20.
   PubMed Web of Science ®Google Scholar
• Novick, D. M., Kreek, M. J. (2008). Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction, 103(6):905–918.
   PubMed Web of Science ®Google Scholar
• Perez, J. F., Farrington, L. A., Pecorano, C., Hutin, Y. J. F., Armstrong, G. L. (2004). Estimated global prevalence of hepatitis C virus infection. Paper presented at 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA; Sept. 30–Oct. 3, 2004.
   Google Scholar
• Reynolds, G. L., Fisher, D. G., Jaffe, A., Edwards, J. (2006). Follow-up for medical care among drug users with hepatitis C. Evaluations & the Health Profession, 29(4):355–367.
   PubMed Web of Science ®Google Scholar
• Rounsaville, B. J., Kosten, T. R. (2000). Treatment for opioid dependence: quality and access. JAMA, 283(10):337–339.
   PubMed Web of Science ®Google Scholar
• Roy, K., Hay, G., Andragetti, R., Taylor, A., Goldgerg, D., Wiessing, L. (2002). Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiology and Infection, 129(3):557–585.
   PubMed Web of Science ®Google Scholar
• Shepard, C. W., Finelli, L., Alter, M. (2005). Global epidemiology of hepatitis C virus infection. Lancet Infectious Diseases, 5:558–567.
   PubMed Web of Science ®Google Scholar
• Sorensen, J. L., Copeland, A. L. (2000). Drug abuse treatment as an HIV prevention strategy: a review. Drug and Alcohol Dependence, 59:17–31.
   PubMed Web of Science ®Google Scholar
• Stein, M. D., Maksad, J., Clarke, J. (2001). Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug and Alcohol Dependence, 61:211–215.
   PubMed Web of Science ®Google Scholar
• Strader, D. B., Wright, T., Thomas, D. L., Seeff, L. B., American Association for the Study of Liver Diseases. (2004). Diagnosis, management, and treatment of Hepatitis C. Hepatology, 39(4):1147–1171.
   PubMed Web of Science ®Google Scholar
• Strauss, S. M., Astone-Twerell, J., Munoz-Plaza, C. E., Des Jarlais, D. C., Gwadz, M., Hagan, H., (2007). Drug treatment program patients’ hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Services Research, 7:39.
   PubMed Web of Science ®Google Scholar
• Stroove, M. A., Gifford, S. M., Dore, G. J. (2005). The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug and Alcohol Dependence, 77:81–86.
   PubMed Web of Science ®Google Scholar
• Sylvestre, D. L. (2002). Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug and Alcohol Dependence, 67:117–123.
   PubMed Web of Science ®Google Scholar
• Sylvestre, D. L. (2005). Approaching treatment for hepatitis C virus infection in substance users. Clinical Infectious Diseases, 41:S79–S82.
   PubMed Web of Science ®Google Scholar
• Thiede, H., Hagan, H., Murrill, C. S. (2000). Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. Journal of Urban Health: Bulletin of the New York Academy of Medicine, 77:331–345.
   PubMed Web of Science ®Google Scholar
• Thorpe, L., Ouellet, L., Hershow, R., Bailey, S., Williams, I., Monterosso, E. (2000). The mulitperson use of non-syringe injection equipment and risk of hepatitis C infection in a cohort of young adult injection drug users, Chicago 1997–1999. Annals of Epidemiology, 10:472–473.
   PubMedGoogle Scholar
• Thorpe, L. E., Ouellet, L. J., Hershow, R., Bailey, S. L., Williams, I. T., Williamson, J., (2002). Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. American Journal of Epidemiology, 155:645–653.
   PubMed Web of Science ®Google Scholar
• Van Thiel, D. H., Anantharaju, A., Creech, S. (2003). Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. American Journal of Gastroenterology, 98(10):2281–2288.
   PubMed Web of Science ®Google Scholar
• Walley, A. Y., White, M. C., Kushel, M. B., Song, Y. S., Tulsky, J. P. (2005). Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment, 28:181–187.
   PubMed Web of Science ®Google Scholar
• Willner-Reid, J., Belendiuk, K. A., Epstein, D. H., Schmittner, J., Preston, K. L. (2008). Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. Journal of Substance Abuse Treatment, 35:78–86.
   PubMed Web of Science ®Google Scholar